Chemical inhibitors of 1700007G11Rik include a variety of compounds that act on different signaling pathways and kinases to achieve functional inhibition. Staurosporine, a potent kinase inhibitor, can disrupt the activity of multiple kinases that are essential for the activity of 1700007G11Rik, thereby reducing its function. Similarly, Wortmannin and LY294002 are both PI3K inhibitors that can suppress PI3K-dependent signaling pathways. The PI3K pathway is crucial for a number of cellular functions and inhibiting this pathway can lead to the functional inhibition of 1700007G11Rik if it is reliant on PI3K signaling. U0126 and PD98059 are both selective for MEK, an upstream kinase in the MAPK/ERK pathway. Since the MAPK/ERK pathway is involved in a multitude of cellular processes, including cell growth and differentiation, inhibition of MEK by these compounds can lead to reduced function of 1700007G11Rik if it is part of this pathway.
Continuing with the theme of pathway-specific inhibition, Rapamycin inhibits mTOR, a key kinase in the mTOR signaling pathway. If 1700007G11Rik functions downstream of mTOR, Rapamycin can functionally inhibit it. SB203580 acts on p38 MAP kinase, which is involved in the response to stress signals; if 1700007G11Rik is a part of the p38 MAPK signaling, SB203580 can inhibit its function. The JNK inhibitor SP600125 can inhibit the function of 1700007G11Rik by inhibiting JNK, assuming JNK signaling is necessary for its function. Erlotinib and Gefitinib, which are EGFR inhibitors, can hinder the function of 1700007G11Rik by blocking EGFR signaling pathways it may be involved in. Sorafenib targets RAF kinases and can inhibit the function of 1700007G11Rik by interrupting the RAF/MEK/ERK signaling cascade. Lastly, Triciribine targets AKT phosphorylation, and its inhibition can suppress the function of 1700007G11Rik if the protein's activity is situated downstream of AKT signaling. Each chemical's mode of action provides a targeted approach to inhibit the functional activity of 1700007G11Rik through interference with specific signaling pathways or kinases that the protein relies on for its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a kinase inhibitor that can inhibit multiple kinases which could be crucial for the activity of 1700007G11Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor and by inhibiting PI3K it can hinder pathways essential for the function of 1700007G11Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, another PI3K inhibitor, can suppress PI3K-dependent signaling pathways involving 1700007G11Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK, which is upstream in the MAPK/ERK pathway, a pathway necessary for 1700007G11Rik function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK, which may lead to the inhibition of 1700007G11Rik function if it is part of the MAPK/ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which if involved in the mTOR signaling pathway with 1700007G11Rik, would result in its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 targets p38 MAP kinase, potentially inhibiting 1700007G11Rik if it plays a role in the p38 MAPK stress response signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, and by inhibiting JNK, it could inhibit the function of 1700007G11Rik if JNK signaling is required. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR inhibitor and could inhibit 1700007G11Rik activity by blocking EGFR signaling pathways involving this protein. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib, another EGFR inhibitor, could hinder the function of 1700007G11Rik by inhibiting essential EGFR signaling pathways. |